Completed PHASE2 INTERVENTIONAL 2-arm NCT02307227

Phase II Study With Trastuzumab + Paclitaxel in Locally Advanced HER2+ Tumors or Epirubicin + Taxotere in HER2- Tumors

Antitumor Immune Responses in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: a Phase II Study With Trastuzumab and Concomitant Weekly Paclitaxel in Patients With HER2+ Tumors or Epirubicin + Taxotere in HER2- Tumors.

Sponsor: Centro di Riferimento Oncologico - Aviano

Conditions Breast Neoplasms

Interventions Docetaxel Epirubicin Paclitaxel Trastuzumab

Updated 5 times since 2017 Last updated: Dec 1, 2014 Started: Apr 30, 2006 Primary completion: Apr 30, 2009 Completion: Apr 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02307227, this PHASE2 trial focuses on Breast Neoplasms and remains completed. Sponsored by Centro di Riferimento Oncologico - Aviano, it has been updated 5 times since 2006, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Apr 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Centro di Riferimento Oncologico - Aviano

Data source: Centro di Riferimento Oncologico - Aviano

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Aviano, Italy